Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSJ148 in Pregnant Women With Primary HCMV Infection
NCT03369912Phase 2Withdrawn
- Sponsor
- Novartis
- Start
- Oct 2018
- Primary completion
- Nov 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of CSJ148 in cytomegalovirus infection (CMV), sponsored by Novartis. Planned start Oct 2018; status: withdrawn.
02
Drugs
CSJ148
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT03369912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03369912.